The Oviduct and Serous Cancer Risk Assessment
Technical Report,30 Sep 2014,29 Sep 2015
The Brigham and Women's Hospital, Inc Boston United States
Pagination or Media Count:
The proposal was designed to address three issues. First could we identify stem cells from the fallopian tube, including from patients with high grade serous cancer HGSC. Second,could we link the molecular abnormalities in cancer associated stem cells and validate them in pathologic material, specifically in what we feel are stem cell outgrowths or SCOUTs and third could we identify molecular alterations that would place the oviduct or the patient at risk for HGSC. In essence we wished to drill down to the cell of origin and link it to cancer risk, identifying an assay that could predict the presence of cancer by analyzing lower genital tract fluids or other samples.